Literature DB >> 24119107

Cytokine profiling in patients with VCP-associated disease.

Eric Dec1, Prachi Rana, Veeral Katheria, Rachel Dec, Manaswitha Khare, Angèle Nalbandian, Szu-Yun Leu, Shlomit Radom-Aizik, Katrina Llewellyn, Lbachir BenMohamed, Frank Zaldivar, Virginia Kimonis.   

Abstract

Valosin containing protein (VCP) disease (also known as Inclusion Body Myopathy, Paget Disease of Bone and Frontotemporal Dementia [IBMPFD] syndrome) is caused by mutations in the gene encoding VCP classically affecting the muscle, bone and brain. Although the genetic cause has been identified, details regarding the pathogenesis of IBMPFD have not been fully determined. Muscle wasting observed in VCP disease is suggestive of cytokine imbalance. We hypothesized that dysfunctional protein homeostasis caused by VCP mutations leads to cytokine imbalances thereby contributing to the muscle wasting phenotype. Circulating levels of interleukin-4 (IL-4), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF a) and epidermal growth factor (EGF) were measured in plasma of patients with VCP disease or controls. TNF a and EGF were significantly altered in VCP disease as compared to control. TNF a was up-regulated, consistent with a cachexia phenotype and EGF levels were increased. No significant differences were observed in IL-4 and IL-6. Cytokine imbalances may be associated with VCP disease and may play a contributory role in VCP myopathy. Further understanding of how VCP dysfunction leads to aberrant protein homeostasis and subsequent cytokine imbalances may also aid in the understanding of other proteinopathies and in the development of novel treatments.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  IBMPFD; VCP; cytokines

Mesh:

Substances:

Year:  2013        PMID: 24119107      PMCID: PMC4057603          DOI: 10.1111/cts.12117

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  27 in total

1.  Global gene profiling of VCP-associated inclusion body myopathy.

Authors:  Angèle Nalbandian; Svetlana Ghimbovschi; Shlomit Radom-Aizik; Eric Dec; Jouni Vesa; Barbara Martin; Susan Knoblach; Charles Smith; Eric Hoffman; Virginia E Kimonis
Journal:  Clin Transl Sci       Date:  2012-04-04       Impact factor: 4.689

Review 2.  Cytokines and their effects on maturation, differentiation and migration of dendritic cells.

Authors:  H Jonuleit; J Knop; A H Enk
Journal:  Arch Dermatol Res       Date:  1996-12       Impact factor: 3.017

3.  Upregulation of endogenous heparin-binding EGF-like growth factor and its role as a survival factor in skeletal myotubes.

Authors:  M Horikawa; S Higashiyama; S Nomura; Y Kitamura; M Ishikawa; N Taniguchi
Journal:  FEBS Lett       Date:  1999-10-01       Impact factor: 4.124

4.  Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone.

Authors:  Sara K Custer; Manuela Neumann; Hongbo Lu; Alexander C Wright; J Paul Taylor
Journal:  Hum Mol Genet       Date:  2010-02-10       Impact factor: 6.150

Review 5.  Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system.

Authors:  Hemmo Meyer; Monika Bug; Sebastian Bremer
Journal:  Nat Cell Biol       Date:  2012-02-02       Impact factor: 28.824

6.  Genotype-phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and/or frontotemporal dementia.

Authors:  S G Mehta; M Khare; R Ramani; G D J Watts; M Simon; K E Osann; S Donkervoort; E Dec; A Nalbandian; J Platt; M Pasquali; A Wang; T Mozaffar; C D Smith; V E Kimonis
Journal:  Clin Genet       Date:  2012-10-04       Impact factor: 4.438

7.  Valosin containing protein associated inclusion body myopathy: abnormal vacuolization, autophagy and cell fusion in myoblasts.

Authors:  Jouni Vesa; Hailing Su; Giles D Watts; Sabine Krause; Maggie C Walter; Barbara Martin; Charles Smith; Douglas C Wallace; Virginia E Kimonis
Journal:  Neuromuscul Disord       Date:  2009-10-13       Impact factor: 4.296

8.  TNF-α triggers rapid membrane insertion of Ca(2+) permeable AMPA receptors into adult motor neurons and enhances their susceptibility to slow excitotoxic injury.

Authors:  Hong Z Yin; Cheng-I Hsu; Stephen Yu; Shyam D Rao; Linda S Sorkin; John H Weiss
Journal:  Exp Neurol       Date:  2012-08-19       Impact factor: 5.330

9.  Tumor necrosis factor inhibits human myogenesis in vitro.

Authors:  S C Miller; H Ito; H M Blau; F M Torti
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

10.  Improved medium with EGF and BSA for differentiated human skeletal muscle cells.

Authors:  J A St Clair; S D Meyer-Demarest; R G Ham
Journal:  Muscle Nerve       Date:  1992-07       Impact factor: 3.217

View more
  5 in total

1.  Cyanidin-3-O-Glucoside Protects PC12 Cells Against Neuronal Apoptosis Mediated by LPS-Stimulated BV2 Microglial Activation.

Authors:  Chayanut Kaewmool; Sasimol Udomruk; Thanyaluck Phitak; Peraphan Pothacharoen; Prachya Kongtawelert
Journal:  Neurotox Res       Date:  2019-09-04       Impact factor: 3.911

2.  Protocatechuic Acid Inhibits Inflammatory Responses in LPS-Stimulated BV2 Microglia via NF-κB and MAPKs Signaling Pathways.

Authors:  Huan-Yu Wang; Hong Wang; Jin-Huan Wang; Qiong Wang; Quan-Feng Ma; Yi-Yang Chen
Journal:  Neurochem Res       Date:  2015-07-02       Impact factor: 3.996

3.  Remifentanil inhibits the inflammatory response of BV2 microglia and protects PC12 cells from damage caused by microglia activation.

Authors:  Yankui Huang; Qingxiang Cai; Huihui Liu; Yong Wang; Wuhua Ma
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

4.  Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.

Authors:  Angèle Nalbandian; Arif A Khan; Ruchi Srivastava; Katrina J Llewellyn; Baichang Tan; Nora Shukr; Yasmin Fazli; Virginia E Kimonis; Lbachir BenMohamed
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

5.  Valosin-containing protein-regulated endoplasmic reticulum stress causes NOD2-dependent inflammatory responses.

Authors:  Maryam Ghalandary; Yue Li; Thomas Fröhlich; Thomas Magg; Yanshan Liu; Meino Rohlfs; Sebastian Hollizeck; Raffaele Conca; Tobias Schwerd; Holm H Uhlig; Philip Bufler; Sibylle Koletzko; Aleixo M Muise; Scott B Snapper; Fabian Hauck; Christoph Klein; Daniel Kotlarz
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.